Follow:
Recent Posts
- AT845: Audentes Therapeutics Begins Recruiting Patients for new Phase 1/2 LOPD Gene Therapy Clinical Trial for Pompe Disease (FORTIS)
- Higher dosing of alglucosidase alfa (ERT) improves outcomes in children with Pompe disease: a clinical study and review of the literature
- Exercise training alone or in combination with high-protein diet in patients with late onset Pompe disease: results of a cross over study
- Actus-101 Gene Therapy Promising Early Results (Phase 1/2 study of AAV2/8-LSPhGAA in Late-Onset Pompe Disease)
- Effects of higher and more frequent dosing of alglucosidase alfa (40mg/kg/week ERT dose) and immunomodulation on long‐term clinical outcome of classic infantile Pompe patients
Categories
- 2020 Top 10
- ACT-101
- AT-GAA (ATB200/AT2221)
- AT845
- Childhood Onset
- Diet
- Enzyme Replacement Therapy (ERT)
- Enzyme Replacement Therapy (ERT) – Experimental
- Exercise
- Future Treatments
- Gene Therapy
- IOPD
- Juvenile Onset
- LOPD
- Lumizyme/Myozyme (alglucosidase alfa)
- Non-Classic Infant Onset
- Phase 1
- Phase 2
- Uncategorized